# A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

> **NCT03311334** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Urothelial Carcinoma
- Primary Peritoneal Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Serous Epithelial Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** DSP-7888 Dosing Emulsion
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03311334
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-14
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-11-29
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate development of the program.
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311334, "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03311334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*